Marsi Bionics Closes a Financing Round of €4.5 Million

Marsi Bionics raises capital. The Spanish company that develops the world’s first pediatric exoskeleton with 360 mobility has closed a round of financing of €4.5 million, led by a consortium that brings together Albp, Ion Ion, and Orilla Asset Management, Verónica’s investment companies Pascual, Jon Riberas and Francisco Riberas, respectively, as reported by the company through the Superior Center for Health Research (Csic) through a statement.

Worldwide, 17 million children cannot walk due to neurological disorders of all kinds. This lack of movement, beyond the difficulty in carrying out any activity, generates, above all, complications that affect the patient’s quality of life and her life expectancy.

In order to provide a solution, Elena García Armada, founder of Marsi Bionics, and her team, in public-private collaboration with the Csic’s Center for Automation and Robotics, have combined healthcare with robotic technology and artificial intelligence to develop the first pediatric exoskeleton that allows these children to interact and connect with their world, dubbed Atlas 2030.

The exoskeleton is a device that adapts to the child’s body to put him in a situation of standing and walking. The equipment has eight joints, with internationally patented technology, which imitate the functioning of natural muscle thanks to the concept of biomimicry. The technology of the joints is elastic, with which the exoskeleton manages to adapt to the muscular condition of the child.

Read more about Marsi Bionics and find the most important business news of the day with our companion app Born2Invest.

Marsi Bionics works in Spain, Italy, Mexico, France, Poland, Italy, and the United Kingdom

At the moment, Atlas 2030 is present in Spain, both in private centers and publicly owned centers, and in countries such as Italy, Mexico, France, Poland, Italy, and the United Kingdom.

In the last two years, the company has begun international marketing of its devices with customers in seven countries and is taking the first steps in public health in Spain. In addition, research and development (R&D) activity has been reinforced thanks to the Strategic Project for Economic Recovery and Transformation (Perte) for Vanguardia Health, with which new gait assistance devices are being created for home environments.

Marsi Bionics aims to invest the capital raised in the round in financing the company’s international expansion, accessing new markets, and in the industrialization of production in order to more quickly meet the current high demand.

The investment consortium brings to the project leadership experience in global industrial companies, with knowledge in the field of robotics and industrial automation being especially relevant, which comes from Verónica Pascual, responsible for the transformation of Asti Mobile Robotics Group.

Marsi Bionics was born in 2013 as a spin-off of the Automation and Robotics Center (CAR), a joint center between the Csic and the Polytechnic University of Madrid (UPM), transferring more than twenty years of know-how in robot locomotion. Exceptionally, the Csic has been part of the shareholders of Marsi Bionics since 2019.

__

(Featured image by  ddimitrova via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.